biotech
biotech Articles
24/7 Wall St. has collected a few pharma and biotech catalysts that are coming up on the calendar in November and December.
Published:
Out of all the biotechs that reported earnings last week, Gilead Sciences seems to be the one that hasn’t been taking its medicine in 2017.
Published:
Gilead Corporation (NASDAQ: GILD) has joined other biotech giants in releasing its earnings for the third quarter of 2017. The company’s market cap was last seen at $101 billion before earnings,...
Published:
Last Updated:
Despite mixed results, with earnings were fairly positive for the quarter, this was not enough to outweigh poor guidance. Shares sank to a new 52-week low.
Published:
Last Updated:
The October 13 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
Published:
Last Updated:
These are four top companies for more aggressive investors looking for health care exposure to consider.
Published:
Last Updated:
The tale of two biotechs appears to be playing out between Aimmune Therapeutics and DBV Technologies, not just for the companies but between analysts as well.
Published:
Last Updated:
At least eight large biotech and pharma outfits are scheduled to report their latest earnings and revenues this coming week.
Published:
Last Updated:
Now there is a new FDA approval Gilead's CAR T lymphoma treatment named Yescarta that has created at least some buzz for Gilead.
Published:
Last Updated:
With Eli Lilly making a huge headline investment in a cancer vaccine, 24/7 Wall St. wanted to look under the hood to see what this deal really entails.
Published:
Last Updated:
Exelixis kicked off the week with a couple updates that are already having a big impact on the stock. These updates came in the form of a key FDA approval.
Published:
Last Updated:
Shares of Spark Therapeutics saw a handy gain to close out the week after the FDA recommended approval of Luxturna.
Published:
Last Updated:
Sometimes it turns out that great growth companies eventually run into the day when getting the growth of the past is not possible. That has been the case of Gilead Sciences since 2015.
Published:
Last Updated:
Infinity Pharmaceuticals saw its shares almost double early on Thursday after the company announced good news.
Published:
Last Updated:
The September 29 short interest data have been compared with the previous report, and short interest in the selected biotech stocks was mixed.
Published:
Last Updated: